Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Galapagos Islands -- Ignore unavailable to you. Want to Upgrade?

To: Lizzie Tudor who wrote (41077)	6/1/2003 9:30:14 PM
From: PuddleGlum	Read Replies (3) \| Respond to of 57110

MLNM also had some good news over the weekend, but I wonder how much of the news had leaked already. Last year there was a big hullaballoo over news that leaked before ASCO. If you want to be (highly) speculative then you could go with a gene therapy play like ARIA, but the big question there is how much they will have to give up in order to get their products into late stage trials. MYGN has always been one that I like, and it moves fast both ways. What's nice is that they have a solid diagnostics division that helps them fund their drug development. CRXA and PRCS look like recovery plays. LGND has already tripled, but it has probably done so with some decent reason. Basically I think that ASCO results are already priced into the biotech sector, so I believe that we will see some selling on the news. But as 007 and I have been discussing, how much higher do we go before the selling starts?